Pharma Two B Ltd.: Clinical Trials

2 trials sponsored by Pharma Two B Ltd., newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed. 2 Phase 3, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 32Completed 2
Phase 21Completed 1

Follow Pharma Two B Ltd.: new trials by email

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
P2B001 0.6/0.75 mg, Rasagiline 0.75 mg, Pramipexole 0.6 mg - Parkinson Disease, Early Parkinson's Disease
Phase 3CompletedPharma Two B Ltd.5442018-01-192023-03-21
Safety, Tolerability and Efficacy of Two Doses of Once Daily P2B001 in Subjects With Early Parkinson's Disease
P2B001 once daily (pramipexole 0.6 mg / rasagiline 0.75 mg),, Placebo, P2B001 once daily (pramipexole 0.3 mg / rasagiline 0.75 mg), - Parkinson's Disease
Phase 2 / Phase 3CompletedPharma Two B Ltd.1492013-12-012023-04-07

Conditions studied

Parkinson Disease (2)

Interventions

Pramipexole (2)  ·  rasagiline (2)

Countries

United States (2)  ·  Canada (1)  ·  Germany (1)  ·  Israel (1)  ·  Spain (1)

Top investigators

Pninit Litman (1)